Consejo de Administración de la EMA: aspectos destacados de la reunión de marzo de 2022
https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2022-meeting
https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2022-meeting
https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-february-2022-prac-meeting_en.pdf
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-march-2022
https://www.ema.europa.eu/documents/other/step-step-guide-how-search-view-download-clinical-trial-clinical-trial-application-sponsors-ctis_en.pdf
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/eudravigilance-evweb-user-manual-version-16_en.pdf
https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring
https://www.ema.europa.eu/en/news/human-medicines-highlights-2021
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-february-2022
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/european-medicines-agency-post-authorisation-procedural-advice-users-centralised-procedure_en.pdf